Key Highlights:
- Immix Biopharma secures investment from Goose Capital, led by Dr. Nancy T. Chang, inventor of blockbuster drugs like XOLAIR®, TROGARZO®, and EBGLYSS®.
- Focus on advancing NXC-201, a BCMA-targeted CAR-T therapy, awarded RMAT designation by FDA and Orphan Drug status in U.S. and EU.
- Investment expected to strengthen commercialization strategy for relapsed/refractory AL Amyloidosis and expand pipeline into other serious diseases.
Strategic Investment Signals Confidence in Immix’s Mission
Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has announced a strategic investment from Houston-based Goose Capital and Dr. Nancy T. Chang, renowned for her pioneering role at Tanox, Inc. The partnership reflects growing confidence in Immix’s mission of “curing the incurable” through next-generation CAR-T therapies.
NXC-201: Redefining Standards in AL Amyloidosis
The lead asset, NXC-201, is a sterically-optimized BCMA-targeted CAR-T therapy featuring a unique “digital filter” to reduce non-specific activation. Interim results from the NEXICART-2 study (NCT06097832) have already met primary endpoints, showing strong potential in relapsed/refractory AL Amyloidosis. The therapy is also being explored for broader applications in other serious diseases.
The Goose Capital Advantage: Leadership and Experience
Dr. Nancy T. Chang, who spearheaded the invention and FDA approval of multiple billion-dollar drugs, brings unmatched expertise in guiding breakthrough therapies from development to commercialization. Goose Capital, comprised of Fortune 500 executives and industry leaders, aims to accelerate Immix’s clinical and commercial trajectory.
Strengthening Future Market Position
The investment comes at a pivotal time as Immix prepares for registration-enabling studies and commercialization strategies for NXC-201. With RMAT and ODD regulatory designations, the company is strategically positioned to deliver transformative therapies to patients with few alternatives.
About the Companies
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing innovative cell therapies for AL Amyloidosis and other serious diseases. Its lead candidate, NXC-201, is currently in U.S.-based multi-center clinical trials and has received RMAT and ODD designations from both FDA and EMA.
Goose Capital is a Houston-based investment firm made up of serial entrepreneurs, industry leaders, and Fortune 500 executives. The firm invests in breakthrough technologies and early-stage startups with the potential to transform industries.
By
